Navigation Links
Vasogen Announces Third Quarter 2007 Results
Date:10/9/2007

ing our ACCLAIM results, the agency strongly

recommended that we conduct a confirmatory trial ("ACCLAIM-II") of

Celacade in NYHA Class II heart failure patients to support a

Pre-market Approval submission for the purpose of achieving

regulatory approval in the United States. The FDA also recommended

that we use a Bayesian approach in the design of the confirmatory

trial. The FDA indicated that they were recommending this approach

specifically because it would allow us to borrow power from the

ACCLAIM trial and also because it has the potential to substantially

reduce the sample size required for a confirmatory study. The planned

trial design for ACCLAIM-II indicates that as few as 300 patients

could provide sufficient data to confirm the finding of the

phase III ACCLAIM trial which demonstrated a 39% reduction

(p=0.0003) in the risk of death or cardiovascular

hospitalizations for patients receiving Celacade in the large

pre-specified subgroup of 689 NYHA class II heart failure patients.

Furthermore, the use of an adaptive clinical trial design also

provides the flexibility to increase the sample size up to

600 patients, should additional data be required. We are preparing to

meet with the FDA again, with the objective of obtaining formal

regulatory agreement with respect to our proposed trial design prior

to the end of the year.

- James B. Young, MD, Chairman, Division of Medicine at the Cleveland

Clinic Foundation and Medical Director, Kaufman Center for Heart

Failure, has agreed to be the Global Principal Investigator and

Chairman of the Steering Committee for the planned ACCLAIM-II study.

Dr. Young, who has played a leading role in numerous multi-center

clinical trials focusing on heart failure and
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... ... ... EDMONTON , March 16 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... , ...
... Mina Mar Group ( http://www.minamargroup.com/ ) as forefront representative of the company,s new expansive corporate interests. , ... , , ... ... ...
... it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of the filing of an,Abbreviated New Drug Application ("ANDA") ... ... , , ... ...
Cached Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 2DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 3DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 4DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 5DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 6Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Simplifying the process for forming compounds that can be ... plastics, has earned one University of Houston chemist a ... of chemistry in the College of Natural Sciences and ... mathematicians and economists in the United States and Canada ...
... productive as conventional systems" The answer is an unqualified, ... most of the time for corn and soybeans according ... Wisconsin-Madison and agricultural consulting firm AGSTAT in the March-April ... their answer on results from the Wisconsin Integrated Cropping ...
... biosensing nanodevice developed by Arizona State University researcher ... security checkpoints and revolutionize health screenings for diseases ... (MRSA). Even more incredible than the device ... worlds tiniest rotary motor: a biological engine measured ...
Cached Biology News:Simplifying manufacture of drugs, plastics earns UH chemist top honor 2Are organic crops as productive as conventional? 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Biology Products: